All AbMole products are for research use only, cannot be used for human consumption.
(R)-Bicalutamide is an active competitive non-steroidal androgen receptor antagonist with an IC50 of 0.17 μM for MDA 453 cells. (R)-Bicalutamide possesses virtually all activities. (R)-Bicalutamide is the leading antiandrogen. (R)-Bicalutamide is used for the treatment of prostate cancer and breast cancer. (R)-Bicalutamide prevents the activation of the androgen receptor and subsequent upregulation of androgen responsive genes by androgenic hormones. In addition, (R)-bicalutamide accelerates the degradation of the androgen receptor.
| Cell Experiment | |
|---|---|
| Cell lines | C4-2 cell |
| Preparation method | Plating exponentially growing C4-2 cells into two 96-well plates and incubating overnight at 37 ˚C. One plate is aspirated and stored at -80 ˚C and the other treated with 10-fold serial concentrations of ridaforolimus (1000 nM to 0.0001 nM) or vehicle (ethanol) after 24h. Following 72 hours culture at 37 ˚C, using the Cy qUANT Cell Proliferation Assay kit the plates to assess simultaneously for cell growth. Bicalutamide and Ridaforolimus combination proliferation assays are performed similarly except cell growth is determined as the change in cell number between vehicle control and compound treated cells after 72 hours in culture. |
| Concentrations | 0-1 μM |
| Incubation time | 72 hours |
| Animal Experiment | |
|---|---|
| Animal models | Male nude mice bearing C4-2 cells |
| Formulation | 4% ethanol, 5% Tween 80, and 5% propylene glycol |
| Dosages | 10 mg/kg |
| Administration | Administered via p.o. |
| Molecular Weight | 430.37 |
| Formula | C18H14F4N2O4S |
| CAS Number | 113299-40-4 |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[5] Ian D Cockshott. Bicalutamide: clinical pharmacokinetics and metabolism
| Related Androgen Receptor Products |
|---|
| LGD-3303
LGD-3303 is a nonsteroidal, nonaromatizable selective androgen receptor ligand that binds to the androgen receptor with high affinity in a radiolabeled to competitive binding assay (Ki=0.9 nM). |
| Ar-V7-IN-1
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications such as prostate cancer. |
| SC912
SC912 is a potent and selective AR-V7 inhibitor with IC50 of 0.36 μM. SC912 binds directly to AR-FL and AR-V7 proteins, inhibites nuclear localization and chromatin binding capabilities. SC912 exerts anticancer activity through inhibition of proliferation, induction of cell cycle arrest and apoptosis. |
| A4B17
A4B17 is an androgen receptor N-terminal inhibitor, which can be used for the research of androgen-responsive prostate cancer. |
| AZ'3137
AZ‘3137 is an orally active PROTAC-type androgen receptor (AR) degrader, with a DC50 value of 22 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
